Table 1 Characteristics of the studies evaluating the association between hs-Tn T and CAC
From: Cardiac troponins and coronary artery calcium score: a systematic review
Author (year) | Country | Age (year) | Population | Study design | Follow-up (year) | Effect size | Finding | Quality assessment |
|---|---|---|---|---|---|---|---|---|
Caselli et al. (2016) [23] | Italy | 60.1 ± 0.5 | Patients with stable angina and unknown CAD | Cross-sectional, n = 297 | - | NR | High CAC score was observed in patients with elevated levels of hs-TnT | Good |
Rusnak et al. (2017) [21] | Germany | 58 | Patients with low to intermediate risk of CAD | Cross-sectional, n = 76 | - | OR(95%CI): 5(1.664–15.025), 0.004a 13.4(1.545–116.233), 0.019b Adjusted for: age, gender, creatinine, uric acid, cholesterol, LDL-C, HDL-C, BMI, triglycerides, arterial hypertension, cardiac family history, smoking, diabetes and NT-proB | Agatston score was significantly correlated with hs-TnT, both in univariable and multivariable linear regression models | Moderate |
Kitagawa et al. (2015) [24] | Japan | 69.2 (9.8) | Stable patients with clinical suspicion of CAD | Cross-sectional, n = 215 |  | OR(95%CI): 1.250 (1.15–1.378), < .0001c 1.101(1.054–1.157)b Adjusted for: age, sex, BMI, average systolic blood pressure, hemoglobin A1c, total cholesterol, logarithm of triglycerides, uric acid, creatinine, smoking status | Serum hs-cTnT is associated with coronary calcium in individuals with suspected coronary disease | Moderate |
Razavi et al. (2021) [25] | USA | 58.9 | Participants with MetS or T2DM | Cohort, n = 574 | 10 | OR(95%CI): Total: 1.55(1.01–2.38),0.04 MS: 1.37(0.84, 2.24),0.2 T2DM: 3.35(1.22, 9.15),0.02 Adjusted for: age, sex, race, education, antihypertensive medication, lipid-lowering medication, glucose-lowering medication, cigarette smoking, waist circumference, blood pressure, fasting blood glucose, fasting serum triglycerides, and total cholesterol/HDL-C ratio | Individuals with a serum hs-cTnT concentration < 3 mg/dL had 55% higher odds of long-term absence of CAC compared to those with a hs-cTnT concentration ≥ 3 mg/dL (p-value = 0.04) | Good |
Tveit et al. (2022) [26] | Norway | 65 | Patients referred for angiographic evaluation of CAD | Cross-sectional, n = 646 | - | B: 0.52(0.25–0.79), p < 0.001 Adjusted for: age, sex, current smoking, history of CAD, diabetes or HF, BMI, SBP, LDL-C and eGFR | There was a graded linear association between higher concentrations of hs-cTnT and higher CAC-score in the total population. | Good |
Lazzarino et al. (2015) [27] | UK | 62.8(5.7) | Disease-free, low-risk participants | Cross-sectional, n = 430 | - | NR | the more accurate a score is in predicting detectable HS-CTnT, the less it is mediated by CAC | Moderate |
Sandoval et al. (2020) [17] | US | 62(10) | Free of clinical CVD | Cohort, n = 6749 | 15 | Cohen’s k: 0.24(0.22–0.26) | Concordance between undetectable/detectable hs-cTnT and CAC demonstrated an agreement rate of 62%, which varied slightly by race/ethnicity. | Good |
Cardinaels et al. (2016) [18] | Netherlands | 55.8 ± 11.0 | Patients with chest discomfort | Cross-sectional, n = 1864 | - | NR | hs-cTnT concentrations were associated with coronary calcium score. | Good |